TraceLink Announces Speaker Lineup and Advisory Board for FutureLink Barcelona

prnewswire | April 15, 2019

TraceLink Announces Speaker Lineup and Advisory Board for FutureLink Barcelona
NORTH READING, Mass., April 15, 2019 /PRNewswire/ -- TraceLink Inc., the world's largest integrated digital supply network providing real-time information sharing for better patient outcomes, today announced the speaker lineup and newly introduced Advisory Board for FutureLink Barcelona. The annual event, taking place June 11-13, 2019 at the Hesperia Barcelona Tower Hotel, sees leaders from across the life sciences industry in Europe, gather to collaborate on the digital transformation of the pharmaceutical supply chain. Speakers will explore how data can drive innovation, transform business operations, and improve patient outcomes with sessions on a range of subject areas including global regulation updates, digital recalls, analytics, supplier collaboration and creating value beyond compliance. "With the FMD deadline passed, FutureLink Barcelona has been designed to address the ongoing business value organizations can achieve from their serialization investment including managing drug recalls and shortages, driving efficiencies through supplier collaboration, engaging patients and caregivers through digital health, and leveraging analytics in the supply chain to make more informed decisions," said Shabbir Dahod, president and CEO, TraceLink. "FutureLink is the only industry event that brings together the end-to-end supply chain, and this is strongly represented in our growing lineup of speakers, who will explore the opportunities derived from a fully integrated digital supply network."

Spotlight

Know more about the global scenario of spurious drugs and why we need a traceability system.

Related News

RESEARCH

Gilead gets WHO cold shoulder for remdesivir in COVID-19, launches speedy defense

Gilead | November 21, 2020

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect on saving lives and other important outcomes for patients, the international body said Thursday. A “disappointed” Gilead immediately fought back. It pointed to remdesivir’s inclusion in several other organizations’ guidelines based on data from a phase 3 trial by the National Institute of Allergy and Infectious Diseases (NIAID), which showed the drug’s use could lead to faster recovery.

Read More

PHARMA TECH

BeiGene-Novartis PD-1 deal; Sinovac vaccine; Celltrion antibody COVID-19 data

Novartis | January 19, 2021

Novartis plunked down up to $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to complement its own checkpoint inhibitor. Hear what BeiGene CEO John Oyler has to say about tislelizumab's position in and outside China. Sinovac's COVID-19 vaccine reported confusing data from Brazil, raising doubt about its true efficacy. Celltron's anti-SARS-CoV-2 antibody improved patients' outcomes in a phase 2/3 trial. And more. Novartis paid $650 million upfront and committed up to $1.55 billion in milestones to license certain rights to BeiGene’s PD-1 inhibitor tislelizumab in major markets outside China. The Swiss pharma is not abandoning its own checkpoint inhibitor spartalizumab despite a recent phase 3 trial failure; instead, it views the two PD-1s as “complementary.” BeiGene retains the right to co-market tislelizumab in North America. The Novartis deal gives the Chinese biotech a chance to get help “learning how to commercialize and build some capabilities” beyond China, BeiGene CEO John Oyler said in an interview. He believes the drug could compete in Asian-prevalent cancer types and its value in large indications will show over time. The CEO also believes the PD-1/L1 class has reached a pricing sweet spot in China where additional major price cuts aren’t likely. Brazilian researchers first said Sinovac’s COVID-19 vaccine, CoronaVac, was 78% effective in a local phase 3 trial. But then, a few days ago, they released new data of just 50.4% efficacy. The gap was caused by the omission of “very mild” infections in the previous data. The misstep led to criticism of the trial organization, Brazil’s Butantan biomedical center, as well as suspicion about CoronaVac’s true efficacy. Turkey just authorized the shot for emergency use based on a reported 91.25% efficacy in an interim analysis of its local trial.

Read More

Drug shortages in US market, compliance gains positive for pharma exporters

Business-standard | April 23, 2020

Concerns over price erosion in the US market, which has impacted the revenue growth of Indian pharma majors over the last four years, could be reversing. The drug shortages in the US market have increased by 37 per cent since December 2017. Kunal Randeria of Antique Stock Broking says drug shortages are at five-year highs and there is a direct correlation between drug shortage and prices. This is evident as price erosion peaked in 2017 when shortages were at their lowest levels. Concerns over price erosion in the US market, which has impacted the revenue growth of Indian pharma majors over the last four years, could be reversing. The drug shortages in the US market have increased by 37 per cent since December 2017. Kunal Randeria of Antique Stock Broking says drug shortages are at five-year highs and there is a direct correlation between drug shortage and prices. This is evident as price erosion peaked in 2017 when shortages were at their lowest levels.

Read More

Spotlight

Know more about the global scenario of spurious drugs and why we need a traceability system.